References
- BaigentCKeechAKearneyPMCholesterol treatment trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536612677816214597
- CannonCPBraunwaldEMcCabeCHPravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350149550415007110
- CannonCPMurphySABraunwaldEIntensive lipid lowering with atorvastatin in coronary diseaseN Engl J Med2005353936 author reply 93–616003832
- CichaISchneiderhan-MarraNYilmazAMonitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivoArterioscler Thromb Vasc Biol20042420465015388523
- CorsiniAThe use of statins in optimising reduction of cardiovascular focus on fluvastatinInt J Clin Pract20045849450315206507
- CorsiniAFarnsworthCCMcGeadyPIncorporation of radiolabeled prenyl alcohols and their analogs into mammalian cell proteins: A useful tool for studying protein prenylationMethods Mol Biol19991161254410399150
- de LemosJABlazingMAWiviottSDEarly intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJAMA200429213071615337732
- EndresMLaufsUEffects of statins on endothelium and signaling mechanismsStroke20043511 Suppl 127081115375300
- HolsteinSAWohlford-LenaneCLConsequences of mevalonate depletion. Differential transcriptional, translational and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoBJ Biol Chem2002277106788211788600
- KinlaySLow-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysisJ Am Coll Cardiol2007492003917512355
- LiaoJKLaufsUPleiotropic effects of statinsAnnu Rev Pharmacol Toxicol2005458911815822172
- McTaggartFBuckettLDavidsonRPreclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorAm J Cardiol2001875A28B32B11137829
- PattiGPasceriVColonnaGAtorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trialJ Am Coll Cardiol2007491272817394957
- PfohlMNaoumovaRPKimKDUse of cholesterol precursors to assess changes in cholesterol synthesis under non-steady-state conditionsEur J Clin Invest19982849169693942
- SchwartzGGOlssonAGEzekowitzMDEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trialJAMA200128517111811277825
- TobertJAHitzenbergerGKukovetzWRRapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductaseAtherosclerosis1982416156918220
- WiviottSDde LemosJACannonCPA tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22Circulation200611314061416534008